NIH R01 · 2025
Retroviral RLI immunomodulatory gene therapy for glioblastoma
PROJECT SUMMARY/ABSTRACT Antitumor immune responses require a functional repertoire of innate and adaptive immune cells. Glioblastoma (GBM), however, harbors a profoundly immunosuppressed microenvironment, particularly its T cell ignorance caused by bone marrow sequestration; T cell exhaustion caused by immune checkpoint molecules on the surface of T cells that suppress T cell function; and impaired memory T-cell responses. Unfortunately, efforts to target the immunosuppressed GBM microenvironment with systemic immunotherapies have not produced meaningful impact in clinical trials. Localized viral treatments have also been investigated for GBM and, while these viruses elicit an anti-tumoral…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.